Coloplast A/S (OTCMKTS:CLPBY) Upgraded at Sanford C. Bernstein

Sanford C. Bernstein upgraded shares of Coloplast A/S (OTCMKTS:CLPBY) from a hold rating to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

A number of other brokerages have also recently weighed in on CLPBY. Hsbc Global Res upgraded shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a report on Monday, November 18th. UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 11th.

Coloplast A/S Stock Performance

Shares of OTCMKTS CLPBY opened at $11.70 on Tuesday. Coloplast A/S has a 1 year low of $10.63 and a 1 year high of $14.34. The company’s 50-day moving average is $11.52 and its 200 day moving average is $12.60. The company has a current ratio of 1.02, a quick ratio of 0.66 and a debt-to-equity ratio of 0.92.

Coloplast A/S (OTCMKTS:CLPBY) last posted its earnings results on Tuesday, November 5th. The company reported $0.08 earnings per share for the quarter. The firm had revenue of $1.02 billion for the quarter. Coloplast A/S had a return on equity of 30.19% and a net margin of 18.69%. On average, analysts anticipate that Coloplast A/S will post 0.36 EPS for the current fiscal year.

Coloplast A/S Increases Dividend

The company also recently disclosed a dividend, which was paid on Friday, December 20th. Investors of record on Monday, December 9th were given a dividend of $0.2435 per share. This is an increase from Coloplast A/S’s previous dividend of $0.05. The ex-dividend date was Monday, December 9th. Coloplast A/S’s dividend payout ratio is 93.94%.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.